T-1095
目录号 : GC52125An SGLT1 and SGLT2 inhibitor
Cas No.:209746-59-8
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
T-1095 is an inhibitor of sodium-glucose cotransporter 1 (SGLT1) and SGLT2 (IC50s = 22.8 and 2.3 µM, respectively).1 Dietary administration of T-1095 (0.01% w/w) reduces blood glucose and HbA1c levels in a rat model of diabetes induced by streptozotocin . It suppresses the development of hyperglycemia and hypertriglyceridemia and reduces HbA1c levels in the KKAγ mouse model of type 2 diabetes. T-1095 exacerbates post-infarction cardiac dysfunction in a rat model of left anterior descending coronary artery ligation-induced myocardial infarction.2
1.Oku, A., Ueta, K., Ishihara, T., et al.T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetesDiabetes48(9)1794-1800(1999) 2.Bruno, J.G., Herman, T.S., Cano, V.L., et al.Selective cytotoxicity of 3-amino-L-tyrosine correlates with peroxidase activityIn Vitro Cell. Dev. Biol. Anim.35(7)376-382(1999)
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.9361 mL | 9.6805 mL | 19.3611 mL |
5 mM | 0.3872 mL | 1.9361 mL | 3.8722 mL |
10 mM | 0.1936 mL | 0.9681 mL | 1.9361 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。